Biotechnology

Vertex Pharma

Vertex Releases New Data on ALYFTREK at European Cystic Fibrosis Conference

ixlayer Launches Remote Care Platform Informed Pain Care in Partnership with Vertex Pharmaceuticals

Vertex Pharma Executive Joy Liu Sells 828 Shares for $364,646

Vertex Pharma CBO Carmen Bozic Sells 1,974 Shares Under 10b5-1 Plan for $888,300

Vertex Pharmaceuticals Announces FDA Acceptance of BLA for Povetacicept to Treat IgA Nephropathy

Waterloo Capital Adds $1.78M Position in VRTX as Insiders Sell; Analyst Ratings Diverge

Vertex Pharmaceuticals Shifts to Integrated Model to Accelerate Journavx Development

Vertex Pharmaceuticals Reports Q1 Revenue Below Expectations, EPS Above Expectations

Vertex Pharma released FY2026 Q1 earnings on May 4 After-Market EST, actual revenue USD 2.987 B (forecast USD 2.998 B), actual EPS USD 4.02 (forecast USD 3.8346)

Vertex Pharma to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 3.002 B, EPS USD 3.8638

Sidra Medicine becomes Qatar's First Hospital to Offer Casgevy

Lbp Am Sa Increased Its Stake in Vertex Pharmaceuticals

Biopharma Companies Outsource Drug Production to Europe

Halozyme and Vertex Enter into Exclusive Drug Delivery Technology Collaboration

Vertex Pharmaceuticals Receives FDA Approval to Expand Indications for Cystic Fibrosis Drugs ALYFTREK and TRIKAFTA

Vertex Pharmaceuticals Submits BLA to FDA for Adult IgA Nephropathy

Morgan Stanley RaisesVRTX Price Target

Vertex Pharmaceuticals' kidney disease drug meets late-stage trial goals

Vertex Pharmaceuticals Announces Positive Results from Phase 4 Study of JOURNAVX for Postoperative Pain Management

Vertex Pharma released FY2025 Q4 earnings on February 12 After-Market EST, actual revenue USD 3.19 B (forecast USD 3.175 B), actual EPS USD 4.6494 (forecast USD 4.588)

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

VRTX

Vertex Pharmaceuticals reported new clinical data for its cystic fibrosis therapies ALYFTREK and TRIKAFTA in pediatric populations, focusing on children as young as 2 years old. The company outlined progress on global regulatory submissions to expand treatment access and highlighted long-term safety findings. These updates aim to broaden the eligible patient pool and extend the franchise's lifecycle, though investors remain cautious about competitive pressures and reliance on the CF portfolio.

Simplywall

Abbvie

Moderna

Vertex Extends Cystic Fibrosis Reach With Pediatric ALYFTREK And TRIKAFTA Data

Vertex Pharmaceuticals (VRTX) stock rose 1.15% to $446.83, outperforming the broader market and competitors on a poor trading day. The S&P 500 fell 2.64%, while peers like AbbVie gained slightly and Krystal Biotech dropped. VRTX marked its third consecutive gain, closing 12.03% below its 52-week high of $507.92. Trading volume reached 1.5 million shares, exceeding the 50-day average.

MarketWatch Automated

S&P 500

Dow Jones Industrial Average

Krystal Biotech

Arcturus Therapeutics

Factset Research

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

ixlayer launched Informed Pain Care, a direct-to-patient telehealth platform developed in collaboration with Vertex Pharmaceuticals. The platform connects patients experiencing acute pain with licensed clinicians for timely evaluation and access to non-opioid treatment options. It aims to address care delays and fragmented pathways by offering symptom-based screening, virtual consultations, and flexible pharmacy fulfillment, thereby expanding access to independent, clinician-led care.

prnewswire

07:01 ETixlayer Launched Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | VRTX Stock News

StockTitan

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | VRTX Stock News

Vertex Pharmaceuticals (VRTX) shares rose 3.13% to $441.74 on Thursday, marking its second consecutive day of gains. Despite this daily increase, the stock underperformed relative to competitors like AbbVie and Krystal Biotech during a broader market rally where the S&P 500 and Dow Jones also gained. Trading volume exceeded its 50-day average, though VRTX remains 13.03% below its 52-week high.

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | VRTX Stock News

Goldman Sachs

GS Hldg R

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | VRTX Stock News

Vertex Pharmaceuticals (VRTX) shares fell 3.04% to $425.09 on Tuesday, underperforming the broader market and competitors like AbbVie despite a positive trading session. This marks the third consecutive day of losses for VRTX, which is now 16.31% below its 52-week high. Trading volume remained below the 50-day average.

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Vertex Pharmaceuticals (VRTX) shares fell 2.04% to $438.40, marking its second consecutive day of losses despite a broader market rally. The stock remains 13.69% below its 52-week high. While competitors like AbbVie and Krystal Biotech also declined, Vertex outperformed them slightly. Trading volume was below the 50-day average.

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Vertex Pharma(VRTX.US)

Vertex Extends Cystic Fibrosis Reach With Pediatric ALYFTREK And TRIKAFTA Data

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

07:01 ETixlayer Launched Informed Pain Care, Expanding Access to Digital Acute Pain Evaluation Nationwide

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference | VRTX Stock News

Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10 | VRTX Stock News

Vertex Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors

Vertex Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day